NIKKEI 225
38,102.44 -712.12 (-1.83%) HANG SENG
17,936.12 -5.66 (-0.03%) CRUDE OIL
80.53 +2.08 (+2.65%) GOLD FUTURES
2,332.70 -16.40 (-0.70%) DOW
38,783.46 +194.30 (+0.50%) Bitcoin GBP
52,582.48 +185.17 (+0.35%)
CDXC Jun 2024 2.500 put
- Simply Wall St.
Here's Why We Think ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Looks Fair
Key Insights ChromaDex to hold its Annual General Meeting on 20th of June Total pay for CEO Rob Fried includes...
- Business Wire
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
LOS ANGELES, June 13, 2024--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride or NRC). Authorized by the U.S. FDA for compounding by 503B outsourcing facilities, pharmaceutical-grade intravenous (IV) and injectable NRC will be available in IV, shot, and push forms exclusively at clinics, with a pr
- Zacks
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.
